NY-ESO-1 expression in solid tumors predicts prognosis

Wang, Huiyu; Chen, Datian; Wang, Runjie; Wen, Qing; Xia, Dandan; Mei, Jie; Xu, Junying; Liu, Chaoying

doi:10.1097/md.0000000000017990

Cited by 13 publications

(10 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, the cytotoxic effects of the TCR-T cells were related to the amount of NY-ESO-1 expressed by the target cells, reflected in the specific secretion of IFN-γ from the TCR-T cells by antigen-loaded T2 cells stimulations in a concentration-dependent way. NY-ESO-1 is a member of the cancer-testis antigens (CTAs) family, which is frequently expressed in diverse epithelial malignancies, such as melanoma, colorectal cancer, breast cancer, and bladder cancer ( 47 , 48 ). NY-ESO-1 is regarded as an ideal immune target of cancer due to its exquisitely specific expression of restriction in normal tissues but a fairly widespread occurrence in cancer ( 49 – 52 ).…”

Section: Discussionmentioning

confidence: 99%

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability

Wang²,

He³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Patients of colorectal cancer (CRC) with microsatellite stability (MSS) show poor clinical response and little beneficial result from the immune-checkpoint inhibitors, due to the ‘cold’ tumor microenvironment. Meanwhile, decitabine can drive the ‘cold’ microenvironment towards ‘hot’ in multiple ways, such as upregulating the tumor associated antigen (TAA) and human leukocyte antigen (HLA) molecular. NY-ESO-1, one of the most important TAAs, can be observably induced in tumors by low dose decitabine, and present itself as ideal targets for antigen specific T cell receptor engineered T (TCR-T) cells. We innovatively used a synergistic tactic, combining decitabine and NY-ESO-1 specific TCR-T cells, for fighting the MSS CRC. Firstly, we confirmed the lysing effect of the NY-ESO-1 TCR-T cells on the NY-ESO-1+ and HLA-A2+ cells in vitro and in vivo. In A375 tumor-bearing mice, the results showed that NY-ESO-1 TCR-T cell therapy could inhibit A375 tumor growth and prolonged the survival time. Furthermore, the synergistic effect of decitabine and NY-ESO-1 TCR-T cells was shown to induce an even higher percentage of tumor cells being lysed in vitro than other control groups, and more potent tumor inhibition and longer survival time were observed in vivo. The innovative synergistic therapeutic strategy of decitabine and TCR-T cells for the CRC with MSS may be also effective in the treatment of other epithelial malignancies. Decitabine may likewise be adopted in combination with other cellular immunotherapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability

Wang²,

He³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…NY-ESO-1 (New York esophageal squamous cell carcinoma), is a cancer testes antigen expressed in spermatocytes, oogonia, the placenta and cancers including 43.9% of cases of HCC [104,105]: At present, only engineered TCR-T approaches targeting NY-ESO-1 have been trialled in HCC (NCT01967823).…”

Section: Other Potential Car-t Targets For Hccmentioning

confidence: 99%

Novel Cellular Therapies for Hepatocellular Carcinoma

Roddy

Meyer

Roddie

2022

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is one of the leading causes of cancer related death worldwide. Most patients present with advanced disease, and current gold-standard management using tyrosine kinase inhibitors or immune checkpoint inhibitors (ICIs) offers modest clinical benefit. Cellular immune therapies targeting HCC are currently being tested in the laboratory and in clinical trials. Here, we review the landscape of cellular immunotherapy for HCC, defining antigenic targets, outlining the range of cell therapy products being applied in HCC (such as CAR-T and TCR-T), and exploring how advanced engineering solutions may further enhance this therapeutic approach.

show abstract

“…New York esophageal squamous cell carcinoma (NY-ESO-1), a promising cancer testes antigen, is expressed by 43.9% of cases of HCC ( 155 , 156 ). Very recently, NY-ESO-1 CAR-T cells constructed by Liu et al.…”

Section: Chimeric Antigen Receptor T Cell Immunotherapymentioning

confidence: 99%

The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy

Zhang

Guanchang²,

Liu

et al. 2022

Front. Endocrinol.

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the major subtype of liver cancer, which ranks sixth in cancer incidence and third in mortality. Although great strides have been made in novel therapy for HCC, such as immunotherapy, the prognosis remains less than satisfactory. Increasing evidence demonstrates that the tumor immune microenvironment (TME) exerts a significant role in the evolution of HCC and has a non-negligible impact on the efficacy of HCC treatment. In the past two decades, the success in hematological malignancies made by chimeric antigen receptor-modified T (CAR-T) cell therapy leveraging it holds great promise for cancer treatment. However, in the face of a hostile TME in solid tumors like HCC, the efficacy of CAR-T cells will be greatly compromised. Here, we provide an overview of TME features in HCC, discuss recent advances and challenges of CAR-T immunotherapy in HCC.

show abstract

NY-ESO-1 expression in solid tumors predicts prognosis

Cited by 13 publications

References 36 publications

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability

Novel Cellular Therapies for Hepatocellular Carcinoma

The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy

Contact Info

Product

Resources

About